Baseline clinical and biochemical characteristics of 55 patients with non-ST segment elevation acute coronary syndromes and angiographically documented coronary artery disease
| Mean (SD) or n (%) | |
|---|---|
| *Total cholesterol > 5.4 mmol/l. | |
| ACE, angiotensin converting enzyme; HDL, high density lipoprotein; HMG-CoA, hydroxymethyl glutaryl coenzyme A; LDL, low density lipoprotein; PTCA, percutaneous transluminal coronary angioplasty. | |
| Age (years) | 62.5 (10.5) |
| Male sex | 41 (74.5%) |
| Systolic blood pressure (mm Hg) | 138.9 (19.7) |
| Diastolic blood pressure (mm Hg) | 77.1 (14.3) |
| Body mass index (kg/m2) | 26.8 (4.1) |
| Previous PTCA | 14 (25.5%) |
| Previous myocardial infarction | 31 (56.4%) |
| Previous unstable angina | 28 (50.9%) |
| Previous stroke | 3 (5.5%) |
| Cardiovascular risk factors | |
| Diabetes mellitus | 7 (12.7%) |
| Hyperlipidaemia* | 27 (49.1%) |
| Hypertension | 29 (52.7%) |
| Smoking | 14 (25.5%) |
| Biochemistry | |
| Cholesterol (mmol/l) | 5.4 (1) |
| HDL cholesterol (mmol/l) | 1 (0.3) |
| LDL cholesterol (mmol/l) | 3.4 (0.8) |
| Triglycerides (mmol/l) | 1.7 (1) |
| Treatment | |
| Aspirin | 40 (72.7%) |
| β Blockers | 24 (43.6%) |
| Nitrates | 27 (49.1%) |
| Calcium channel antagonists | 30 (54.5%) |
| ACE inhibitors | 10 (18.2%) |
| HMG-CoA reductase inhibitors | 13 (23.6%) |